Accounts Payable Specialist / Kreditorenbuchhalter (f / x / m)

Your mission

About the Role

The Accounts Payable Specialist will be responsible for managing a high volume of invoices across both Germany and the United States, ensuring accurate processing and efficient payments. This individual will play a critical role in maintaining CatalYm’s reputation for fiscal reliability by ensuring that no payments are delayed, all invoices are compliant with accounting and tax standards, and vendor relationships remain positive and professional.

This is an ideal opportunity for an experienced A / P professional who enjoys working in a fast-paced, international biotech environment and values precision, accountability, and continuous improvement.

Key Responsibilities

• Process, verify, and post a high volume of vendor invoices for both German and U.S. entities, ensuring compliance with CatalYm policies and local accounting regulations.
• Manage invoice approval workflows, coding accuracy, and purchase order matching.
• Ensure compliance with German GAAP (HGB) and U.S. GAAP, including proper VAT (Umsatzsteuer) and sales / use tax treatment.
• Handle cross-border payments, including multi-currency processing, foreign exchange considerations, and intercompany transactions.
• Ensure timely, accurate vendor payments—no late payments.
• Reconcile vendor accounts and resolve discrepancies in a proactive, solutions-oriented manner.
• Support month-end and year-end close activities for both Germany and the U.S. by preparing accruals, reconciliations, and audit-ready documentation.
• Assist in internal and external audits, providing complete and accurate documentation as requested.
• Maintain and organize A / P records in accordance with German GoBD and U.S. documentation standards.
• Identify opportunities to streamline A / P workflows, automate processes, and enhance payment efficiency.

Your profile

Preferred Qualifications

Personal Attributes

Why us?

About us

CatalYm is a biotech company based in Martinsried near Munich, developing innovative immunotherapies to transform cancer patients’ lives by effectively engaging their own immune systems to combat this malignant disease. We are now advancing to Phase 2b studies to confirm visugromab, our lead antibody, that has demonstrated durable anti-tumor efficacy with long-lasting objective responses in relapsed and refractory metastatic solid tumor patients in combination with anti-PD-1 treatment. Our mission is to rapidly bring our next-generation immuno-oncology products to patients in need. Are you ready to board the fast-accelerating visugromab train in Martinsried? Then join us!